Publication:
Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study

0
0

Issued Date

2021

Resource Type

Article

Language

eng

File Type

application/pdf

ISSN

14732130

DOI

10.1111/jocd.13648

Other identifier(s)

2-s2.0-85089557074

Rights Holder(s)

มหาวิทยาลัยศรีนครินทรวิโรฒ

Bibliographic Citation

Journal of Cosmetic Dermatology. Vol 20, No.3 (2021), p.812-818

Suggested Citation

Kanokrungsee S., Pruettivorawongse D., Rajatanavin N. Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study. Journal of Cosmetic Dermatology. Vol 20, No.3 (2021), p.812-818. doi:10.1111/jocd.13648 Retrieved from: https://hdl.handle.net/20.500.14740/7873

Title

Clinical outcomes of topical bimatoprost for nonsegmental facial vitiligo: A preliminary study

Author(s)

Kanokrungsee S.
 Pruettivorawongse D.
 Rajatanavin N.

Abstract

Background: Vitiligo is a common acquired pigmentary disorder. Bimatoprost ophthalmic solution was indicated in the treatment of open-angle glaucoma and eyebrow hypotrichosis. However, lid hyperpigmentation was reported as a complication. Objective: To study the efficacy and safety of 0.01% bimatoprost solution compared with 0.1% tacrolimus ointment in patients with nonsegmental facial vitiligo. Methods: Patients with more than 2 vitiliginous patches on the face were enrolled. Vitiliginous patches were randomized to receive topical 0.1% tacrolimus ointment or 0.01% bimatoprost ophthalmic solution, applied twice daily for 12 weeks. The vitiligo surface area (VSA, cm2) was calculated, and the percentage of repigmentation was assessed. Results: Ten patients completed the study. At the baseline, the mean VSA was comparable between the two groups. By week 12, the VSA decreased at a statistically significant level among both groups compared to the baseline (P <.05). However, there was not a statistically significant difference between both groups. In terms of repigmentation at week 12, 20% of the patients in the bimatoprost group and 10% in the tacrolimus group achieved >50% repigmentation; the overall grading score between two groups were not different at a statistically significant level. The side effects of bimatoprost were reported as itching and burning. There were no changes in intraocular pressure in 2 patients who had lid involvement. Conclusion: Topical bimatoprost solutions were safe and effective for the treatment of nonsegmental facial vitiligo with comparable results to tacrolimus ointment. It can be considered as an alternative treatment for facial vitiligo. © 2020 Wiley Periodicals LLC

Subject(s)

Bimatoprost
 Tacrolimus
 Bimatoprost
 Tacrolimus
 Adult
 Article
 Body mass
 Burning sensation
 Clinical article
 Clinical assessment tool
 Clinical outcome
 Controlled study
 Digital imaging
 Disease duration
 Drug efficacy
 Drug safety
 Face disorder
 Family history
 Female
 Human
 Hyperthyroidism
 Hypertrichosis
 Image analysis
 Intraocular pressure
 Male
 Middle aged
 Nonsegmental facial vitiligo
 Patient
 Photography
 Pruritus
 Randomized controlled trial
 Side effect
 Single blind procedure
 Skin examination
 Skin pigmentation
 Skin repigmentation
 Surface area
 Thailand
 Treatment duration
 Vitiligo
 Vitiligo Disease Activity Score
 Vitiligo surface area
 Face
 Treatment outcome
 Vitiligo
 Bimatoprost
 Face
 Humans
 Tacrolimus
 Treatment Outcome
 Vitiligo

View online Resources

Research Projects

Organizational Units

Journal Issue

URI

https://hdl.handle.net/20.500.14740/7873

Collections

Scopus: Year 1983-2021

Endorsement

Review

Supplemented By

Referenced By